{"id":"W2586322118","doi":"10.1093/annonc/mdw435.42","title":"Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Vancouver General Hospital; BC Cancer Agency; Ottawa Hospital; University of British Columbia; McGill University","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Gefitinib; Clinical endpoint; Discontinuation; Lung cancer; T790M; Gastroenterology; Oncology; Cancer; Clinical trial; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001535669,0.0008747565,0.002232825,0.0003641451,0.0003247939,0.001117318,0.0007048753,0.001355875,0.002759208],"category_scores_gemma":[0.001696318,0.0003122959,0.002339948,0.0005018297,0.0007258388,0.001632124,0.0003890273,0.002780446,0.0006920007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008878811,"about_ca_system_score_gemma":0.001030167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00142971,"about_ca_topic_score_gemma":0.00485979,"domain_scores_codex":[0.9993375,0.0003326962,0.0000596686,0.00009707714,0.00003929632,0.000133742],"domain_scores_gemma":[0.9991615,0.0002428058,0.0001729441,0.00004123058,0.00003436937,0.0003470743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9047127,0.002584833,0.007822066,0.0007472924,0.002258139,0.0001424361,0.0001230166,0.001988204,0.005115642,0.0002749987,0.004235988,0.06999471],"study_design_scores_gemma":[0.6600848,0.2710507,0.05057747,0.0002114234,0.003955468,0.0008388043,0.0003827739,0.003640052,0.002154552,0.001396529,0.005586443,0.000120927],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984161,0.009957675,0.0002106223,0.001447976,0.0003735622,0.0001989766,0.001105911,0.00007539471,0.002468894],"genre_scores_gemma":[0.993385,0.003009601,0.0003078321,0.000780691,0.0002136751,0.0001294326,0.001207884,0.00001603448,0.0009499224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002759208,"threshold_uncertainty_score":0.009230494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06096577234198846,"score_gpt":0.4218890440377996,"score_spread":0.3609232716958111,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}